Lloyd Emerson Johnson
Lloyd Emerson Johnson's purchase track record
Lloyd Emerson Johnson has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/7/2025 | BZH | $1.01M | -2.3% | +6.1% | +6.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Apogee Enterprises Completes GroGlass Acquisition. Apogee Enterprises has completed the acquisition of GroGlass, a move intended to expand its Performance Surfaces segment. This strategic addition aims to broaden the company's product offerings within that specific business unit. The stock is currently trading near its 52-week low, with an average analyst target price of $44.00.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
VSEC Reports Q2 2026 Results and Cited as Volatile Stock. VSE Corporation held its Q2 2026 earnings call, providing an update on its recent performance. In a separate market commentary, VSEC was listed among stocks noted for high volatility and risk. The earnings discussion and the volatility focus both draw attention to the company's current market dynamics.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Beazer Homes Featured in Zacks and Broker Stock Lists. Beazer Homes USA was highlighted in recent Zacks.com features and listed among stocks favored by brokers during a period of market uncertainty. These mentions suggest continued analyst attention to the homebuilder. The stock is currently trading above its average analyst target price, which ranges from $22.00 to $33.00.
Transaction History
| HAE | ▲ Buy | Grant | 2,538 | — | 7/24/2026 | View on chart |
| APOG | ▲ Buy | Option Exercise | 2,883 | — | 1/2/2026 | View on chart |
| VSEC | ▲ Buy | Grant | 745 | $0 | 1/2/2026 | View on chart |
| BZH | ▲ Buy | Grant | 7,199 | $0 | 11/17/2025 | View on chart |
| HAE | ▲ Buy | Grant | 2,693 | — | 7/24/2025 | View on chart |
| BZH | ▲ Buy | Open Market | 22,500 | $500K | 2/10/2025 | View on chart |
| BZH | ▲ Buy | Open Market | 22,500 | $510K | 2/7/2025 | View on chart |
| VSEC | ▲ Buy | Grant | 1,454 | $0 | 1/2/2025 | View on chart |
| BZH | ▲ Buy | Grant | 5,051 | $0 | 11/15/2024 | View on chart |
| HAE | ▲ Buy | Grant | 2,207 | — | 7/25/2024 | View on chart |
| APOG | ▼ Sell | Open Market | 24,000 | $1.5M | 5/2/2024 | View on chart |
| VSEC | ▲ Buy | Grant | 1,737 | $0 | 1/2/2024 | View on chart |
| BZH | ▲ Buy | Grant | 6,024 | $0 | 11/20/2023 | View on chart |
| HAE | ▲ Buy | Grant | 2,226 | — | 8/4/2023 | View on chart |
| VSEC | ▲ Buy | Grant | 2,146 | $0 | 1/3/2023 | View on chart |
| BZH | ▲ Buy | Grant | 14,181 | $0 | 11/14/2022 | View on chart |
| HAE | ▲ Buy | Grant | 2,730 | — | 8/5/2022 | View on chart |
| VSEC | ▲ Buy | Grant | 1,369 | $0 | 7/27/2022 | View on chart |
| BZH | ▲ Buy | Grant | 7,679 | $0 | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump
Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.